PATTIES FOODS - Frankfurt Stock Exchang (PH4) - Total Liabilities
Based on the latest financial reports, PATTIES FOODS - Frankfurt Stock Exchang (PH4) has total liabilities worth €876.86 Million EUR (≈ $1.03 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PATTIES FOODS - Frankfurt Stock Exchang cash flow conversion to assess how effectively this company generates cash.
PATTIES FOODS - Frankfurt Stock Exchang - Total Liabilities Trend (2020–2024)
This chart illustrates how PATTIES FOODS - Frankfurt Stock Exchang's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of PATTIES FOODS - Frankfurt Stock Exchang to evaluate the company's liquid asset resilience ratio.
PATTIES FOODS - Frankfurt Stock Exchang Competitors by Total Liabilities
The table below lists competitors of PATTIES FOODS - Frankfurt Stock Exchang ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advanced Wireless Semiconductor Co
TWO:8086
|
Taiwan | NT$2.29 Billion |
|
Hidrovias do Brasil S.A
SA:HBSA3
|
Brazil | R$4.33 Billion |
|
BEH Property Co Ltd
SHG:600791
|
China | CN¥13.77 Billion |
|
PMB Technology Bhd
KLSE:7172
|
Malaysia | RM1.22 Billion |
|
Hangzhou MDK Opto Electronic Corp. Ltd. A
SHG:688079
|
China | CN¥1.92 Billion |
|
Henan Ancai Hi-tech Co Ltd
SHG:600207
|
China | CN¥4.02 Billion |
|
Irish Continental Group PLC
IR:IR5B
|
Ireland | €393.60 Million |
|
Sparebanken Sor
OL:SOR
|
Norway | Nkr158.47 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down PATTIES FOODS - Frankfurt Stock Exchang's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PATTIES FOODS - Frankfurt Stock Exchang (PH4) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PATTIES FOODS - Frankfurt Stock Exchang's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PATTIES FOODS - Frankfurt Stock Exchang (2020–2024)
The table below shows the annual total liabilities of PATTIES FOODS - Frankfurt Stock Exchang from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.03 Billion ≈ $1.20 Billion |
-14.57% |
| 2023-12-31 | €1.21 Billion ≈ $1.41 Billion |
+1.35% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
+11.71% |
| 2021-12-31 | €1.06 Billion ≈ $1.24 Billion |
+31.69% |
| 2020-12-31 | €808.29 Million ≈ $944.98 Million |
-- |
About PATTIES FOODS - Frankfurt Stock Exchang
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more